Skip to main content
Erschienen in: Familial Cancer 2/2008

01.06.2008

Gonadal mosaicism and familial adenomatous polyposis

verfasst von: Angela L. Schwab, Thérèse M. F. Tuohy, Michelle Condie, Deborah W. Neklason, Randall W. Burt

Erschienen in: Familial Cancer | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

De novo mutations in the adenomatous polyposis coli (APC) gene are estimated to constitute approximately 25% of familial adenomatous polyposis (FAP) cases. A small percentage of these arise in the mosaic form, affecting only a subset of cells in the affected individual. A family is described here whereby an unaffected mother with no detectible mutation in APC, transmitted the identical APC c.4729G>T (p.Glu1577X) mutation to two children. A third child, with the same APC allelic haplotype received a normal APC allele, suggesting that the mutation originated in the gonadal tissues of the mother. These results underscore the utility of mutation-specific genetic testing for the parents and siblings of a proband of an adult-onset disease, even if the proband appears to have a de novo mutation. Parents who test negative for the mutation should be counseled about the possibility of having another affected child due to gonadal mosaicism.
Literatur
1.
Zurück zum Zitat Petersen GM, Slack J, Nakamura Y (1991) Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 100(6):1658–1664 JunPubMed Petersen GM, Slack J, Nakamura Y (1991) Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 100(6):1658–1664 JunPubMed
3.
Zurück zum Zitat Kadmon M, Tandara A, Herfarth C (2001) Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis 16(2):63–75 AprPubMedCrossRef Kadmon M, Tandara A, Herfarth C (2001) Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis 16(2):63–75 AprPubMedCrossRef
4.
Zurück zum Zitat Cetta F, Curia MC, Montalto G et al (2001) Thyroid carcinoma usually occurs in patients with familial adenomatous polyposis in the absence of biallelic inactivation of the adenomatous polyposis coli gene. J Clin Endocrinol Metab 86(1):427–432 JanPubMedCrossRef Cetta F, Curia MC, Montalto G et al (2001) Thyroid carcinoma usually occurs in patients with familial adenomatous polyposis in the absence of biallelic inactivation of the adenomatous polyposis coli gene. J Clin Endocrinol Metab 86(1):427–432 JanPubMedCrossRef
5.
Zurück zum Zitat Cetta F, Montalto G, Gori M, Curia MC, Cama A, Olschwang S (2000) Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. Journal of Clin Endocrinol Metabolism 85(1):286–292 JanCrossRef Cetta F, Montalto G, Gori M, Curia MC, Cama A, Olschwang S (2000) Germline mutations of the APC gene in patients with familial adenomatous polyposis-associated thyroid carcinoma: results from a European cooperative study. Journal of Clin Endocrinol Metabolism 85(1):286–292 JanCrossRef
6.
Zurück zum Zitat Wallace MH, Phillips RK (1998) Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 85(6):742–750 JunPubMedCrossRef Wallace MH, Phillips RK (1998) Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 85(6):742–750 JunPubMedCrossRef
7.
Zurück zum Zitat Rustin RB, Jagelman DG, McGannon E, Fazio VW, Lavery IC, Weakley FL (1990) Spontaneous mutation in familial adenomatous polyposis. Dis Colon Rectum 33(1):52–55 JanPubMedCrossRef Rustin RB, Jagelman DG, McGannon E, Fazio VW, Lavery IC, Weakley FL (1990) Spontaneous mutation in familial adenomatous polyposis. Dis Colon Rectum 33(1):52–55 JanPubMedCrossRef
8.
Zurück zum Zitat Davidson S, Leshanski L, Rennert G, Eidelman S, Amikam D (2002) Maternal mosaicism for a second mutational event—a novel deletion—in a familial adenomatous polyposis family harboring a new germ-line mutation in the alternatively spliced-exon 9 region of APC. Hum Mutat 19(1):83–84 JanPubMedCrossRef Davidson S, Leshanski L, Rennert G, Eidelman S, Amikam D (2002) Maternal mosaicism for a second mutational event—a novel deletion—in a familial adenomatous polyposis family harboring a new germ-line mutation in the alternatively spliced-exon 9 region of APC. Hum Mutat 19(1):83–84 JanPubMedCrossRef
9.
Zurück zum Zitat Niu DM, Huang JY, Li HY et al (2006) Paternal gonadal mosaicism of NIPBL mutation in a father of siblings with Cornelia de Lange syndrome. Prenat Diagn 26(11):1054–1057 NovPubMedCrossRef Niu DM, Huang JY, Li HY et al (2006) Paternal gonadal mosaicism of NIPBL mutation in a father of siblings with Cornelia de Lange syndrome. Prenat Diagn 26(11):1054–1057 NovPubMedCrossRef
10.
Zurück zum Zitat Depienne C, Arzimanoglou A, Trouillard O et al (2006) Parental mosaicism can cause recurrent transmission of SCN1A mutations associated with severe myoclonic epilepsy of infancy. Hum Mutat 27(4):389 AprPubMedCrossRef Depienne C, Arzimanoglou A, Trouillard O et al (2006) Parental mosaicism can cause recurrent transmission of SCN1A mutations associated with severe myoclonic epilepsy of infancy. Hum Mutat 27(4):389 AprPubMedCrossRef
11.
Zurück zum Zitat Gennaro E, Santorelli FM, Bertini E et al (2006) Somatic and germline mosaicisms in severe myoclonic epilepsy of infancy. Biochem Biophys Res Commun 341(2):489–493 Mar 10PubMedCrossRef Gennaro E, Santorelli FM, Bertini E et al (2006) Somatic and germline mosaicisms in severe myoclonic epilepsy of infancy. Biochem Biophys Res Commun 341(2):489–493 Mar 10PubMedCrossRef
12.
Zurück zum Zitat Byers PH, Tsipouras P, Bonadio JF, Starman BJ, Schwartz RC (1988) Perinatal lethal osteogenesis imperfecta (OI type II): a biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen. Am J Hum Genet 42(2):237–248 FebPubMed Byers PH, Tsipouras P, Bonadio JF, Starman BJ, Schwartz RC (1988) Perinatal lethal osteogenesis imperfecta (OI type II): a biochemically heterogeneous disorder usually due to new mutations in the genes for type I collagen. Am J Hum Genet 42(2):237–248 FebPubMed
13.
Zurück zum Zitat Cohen-Solal L, Bonaventure J, Maroteaux P (1991) Dominant mutations in familial lethal and severe osteogenesis imperfecta. Hum Genet 87(3):297–301 JulPubMedCrossRef Cohen-Solal L, Bonaventure J, Maroteaux P (1991) Dominant mutations in familial lethal and severe osteogenesis imperfecta. Hum Genet 87(3):297–301 JulPubMedCrossRef
14.
Zurück zum Zitat Grange DK, Balfour IC, Chen SC, Wood EG (1998) Familial syndrome of progressive arterial occlusive disease consistent with fibromuscular dysplasia, hypertension, congenital cardiac defects, bone fragility, brachysyndactyly, and learning disabilities. Am J Med Genet 75(5):469–480 Feb 17PubMedCrossRef Grange DK, Balfour IC, Chen SC, Wood EG (1998) Familial syndrome of progressive arterial occlusive disease consistent with fibromuscular dysplasia, hypertension, congenital cardiac defects, bone fragility, brachysyndactyly, and learning disabilities. Am J Med Genet 75(5):469–480 Feb 17PubMedCrossRef
15.
Zurück zum Zitat Lund AM, Nicholls AC, Schwartz M, Skovby F (1997) Parental mosaicism and autosomal dominant mutations causing structural abnormalities of collagen I are frequent in families with osteogenesis imperfecta type III/IV. Acta Paediatr 86(7):711–718 JulPubMedCrossRef Lund AM, Nicholls AC, Schwartz M, Skovby F (1997) Parental mosaicism and autosomal dominant mutations causing structural abnormalities of collagen I are frequent in families with osteogenesis imperfecta type III/IV. Acta Paediatr 86(7):711–718 JulPubMedCrossRef
16.
Zurück zum Zitat Raghunath M, Mackay K, Dalgleish R, Steinmann B (1995) Genetic counselling on brittle grounds: recurring osteogenesis imperfecta due to parental mosaicism for a dominant mutation. Eur J Pediatr 154(2):123–129 FebPubMedCrossRef Raghunath M, Mackay K, Dalgleish R, Steinmann B (1995) Genetic counselling on brittle grounds: recurring osteogenesis imperfecta due to parental mosaicism for a dominant mutation. Eur J Pediatr 154(2):123–129 FebPubMedCrossRef
17.
Zurück zum Zitat Somprasit C, Aguinaga M, Cisneros PL et al (2004) Paternal gonadal mosaicism detected in a couple with recurrent abortions undergoing PGD: FISH analysis of sperm nuclei proves valuable. Reprod Biomed Online 9(2):225–230 AugPubMedCrossRef Somprasit C, Aguinaga M, Cisneros PL et al (2004) Paternal gonadal mosaicism detected in a couple with recurrent abortions undergoing PGD: FISH analysis of sperm nuclei proves valuable. Reprod Biomed Online 9(2):225–230 AugPubMedCrossRef
18.
Zurück zum Zitat den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15(1):7–12CrossRef den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15(1):7–12CrossRef
19.
Zurück zum Zitat Farrington SM, Dunlop MG (1999) Mosaicism and sporadic familial adenomatous polyposis. Am J Hum Genet 64(2):653–658 FebPubMedCrossRef Farrington SM, Dunlop MG (1999) Mosaicism and sporadic familial adenomatous polyposis. Am J Hum Genet 64(2):653–658 FebPubMedCrossRef
20.
Zurück zum Zitat Aretz S, Stienen D, Friedrichs N et al (2007) Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum Mutat 28(10):985–992PubMedCrossRef Aretz S, Stienen D, Friedrichs N et al (2007) Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum Mutat 28(10):985–992PubMedCrossRef
21.
Zurück zum Zitat Hes FJ, Nielsen M, Bik EC, et al (2007) Somatic APC Mosaicism: An Underestimated Cause Of Polyposis Coli. Gut (in press) Hes FJ, Nielsen M, Bik EC, et al (2007) Somatic APC Mosaicism: An Underestimated Cause Of Polyposis Coli. Gut (in press)
22.
Zurück zum Zitat Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3(2):121–125PubMedCrossRef Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 3(2):121–125PubMedCrossRef
23.
Zurück zum Zitat Aretz S, Uhlhaas S, Caspari R et al (2004) Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 12(1):52–58 JanPubMedCrossRef Aretz S, Uhlhaas S, Caspari R et al (2004) Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis. Eur J Hum Genet 12(1):52–58 JanPubMedCrossRef
Metadaten
Titel
Gonadal mosaicism and familial adenomatous polyposis
verfasst von
Angela L. Schwab
Thérèse M. F. Tuohy
Michelle Condie
Deborah W. Neklason
Randall W. Burt
Publikationsdatum
01.06.2008
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2008
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-007-9169-1

Weitere Artikel der Ausgabe 2/2008

Familial Cancer 2/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.